"Macular Edema" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
- Irvine-Gass Syndrome
- Irvine Gass Syndrome
- Syndrome, Irvine-Gass
- Cystoid Macular Edema, Postoperative
Macular Edema, Cystoid
- Macular Edema, Cystoid
- Edema, Cystoid Macular
- Cystoid Macular Dystrophy
- Macular Dystrophy, Dominant Cystoid
- Central Retinal Edema, Cystoid
- Cystoid Macular Edema
Below are MeSH descriptors whose meaning is more general than "Macular Edema".
Below are MeSH descriptors whose meaning is more specific than "Macular Edema".
This graph shows the total number of publications written about "Macular Edema" by people in this website by year, and whether "Macular Edema" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Macular Edema" by people in Profiles.
Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis. Value Health. 2022 10; 25(10):1705-1716.
Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2. Int J Mol Sci. 2022 Jul 16; 23(14).
Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology. 2022 06; 129(6):605-613.
Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun; 29(6):547-554.
Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Eur J Ophthalmol. 2021 Mar; 31(2):612-619.
Long-term outcomes after intravitreal dexamethasone treatment in steroid responders. Acta Diabetol. 2019 Jun; 56(6):675-680.
Dexamethasone and Anti-VEGF Combination Therapy for the Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2019 01 01; 50(1):4-7.
Reply. Am J Ophthalmol. 2018 02; 186:165.
Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome. Am J Ophthalmol. 2017 Dec; 184:121-128.
Role of Disorganization of Retinal Inner Layers as an Optical Coherence Tomography Biomarker in Diabetic and Uveitic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2017 04 01; 48(4):282-288.